On August 2, the Institute of Hematology and Immunology received samples of the first batch of Rivaxan, a drug used to treat patients with bleeding disorders. This is the product of a strategic alliance between MedSol Cuba Laboratories and the State Enterprise ACADEMPHARM. The event was attended by the leadership of MedSol Cuba Laboratories and BioCubaFarmaSA.
19.09.2025
Interesting in the press center
Potential of RANOLAZINE in improving the quality of life of patients with coronary heart disease. – Download the article
09.10.2019
Ranolazine-NAN – international standards in the treatment of coronary heart disease
12.07.2019
Let there be light! Administration of HeptalNAN in psychiatry
01.07.2019
Ratsium
13.12.2019